Literature DB >> 11927014

Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT.

Hideki Harada1, Kaoru Saijo, Satoru Watanabe, Koji Tsuboi, Tadao Nose, Isamu Ishiwata, Tadao Ohno.   

Abstract

An anchorage-dependent Wilms tumor cell line HFWT was found to stimulate selective and remarkable expansion of human natural killer (NK) cells from human peripheral blood mononuclear cells (PBMC). After PBMC of healthy donors were cultured on irradiated HFWT cells for 10 - 21 days, the lymphocytes expanded 58- to 401-fold. This NK cell expansion required direct contact of PBMC with live, but not fixed, HFWT cells. The PBMC from an end-stage brain tumor patient also expanded 156-fold, whereas those cultured with irradiated NK-sensitive K562 grew only 30.5-fold. CD16+ CD56+ NK cells accounted for more than 70% of the population expanded on HFWT cells. No essential difference in expression of NK receptors was observed in the expanded NK cells on HFWT and K562 and without feeder cells. The expanded NK cells killed not only fresh HFWT cells but, unexpectedly, also MHC class I-expressing autologous brain tumor cells at an effector/target ratio of 4 for 24 h. These results will contribute to the development of a large-scale preparation method for human NK cells, which will aid studies of NK cell biology and possible treatment of brain tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927014      PMCID: PMC5926967          DOI: 10.1111/j.1349-7006.2002.tb02174.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  29 in total

Review 1.  Biology and clinical relevance of human natural killer cells.

Authors:  M J Robertson; J Ritz
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

2.  Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.

Authors:  H Rabinowich; P Sedlmayr; R B Herberman; T L Whiteside
Journal:  Cell Immunol       Date:  1991-07       Impact factor: 4.868

3.  Participation of the CD94 receptor complex in costimulation of human natural killer cells.

Authors:  S D Voss; J Daley; J Ritz; M J Robertson
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

4.  Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines.

Authors:  B Perussia; C Ramoni; I Anegon; M C Cuturi; J Faust; G Trinchieri
Journal:  Nat Immun Cell Growth Regul       Date:  1987

5.  Targeting of human dendritic cells by autologous NK cells.

Authors:  J L Wilson; L C Heffler; J Charo; A Scheynius; M T Bejarano; H G Ljunggren
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

6.  Carcinoembryonic proteins produced by Wilms' tumor cells in vitro and in vivo.

Authors:  I Ishiwata; I Ono; C Ishiwata; M Soma; T Nakaguchi; K Ohara; M Hirano; H Ishikawa
Journal:  Exp Pathol       Date:  1991

7.  In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells.

Authors:  C Kim; M Matsumura; K Saijo; T Ohno
Journal:  Cancer Immunol Immunother       Date:  1998-10       Impact factor: 6.968

8.  NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor.

Authors:  A G Brooks; P E Posch; C J Scorzelli; F Borrego; J E Coligan
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

9.  Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes.

Authors:  H Tsurushima; S Q Liu; K Tuboi; A Matsumura; Y Yoshii; T Nose; K Saijo; T Ohno
Journal:  Jpn J Cancer Res       Date:  1999-05

10.  A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562.

Authors:  J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

View more
  13 in total

1.  A GFP-transfected HFWT cell line, GHINK-1, as a novel target for non-RI activated natural killer cytotoxicity assay.

Authors:  Hideki Harada; Kaoru Saijo; Isamu Ishiwata; Tadao Ohno
Journal:  Hum Cell       Date:  2004-03       Impact factor: 4.174

2.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

Review 3.  NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation.

Authors:  Shatha Farhan; Dean A Lee; Richard E Champlin; Stefan O Ciurea
Journal:  Immunotherapy       Date:  2012-02-13       Impact factor: 4.196

4.  Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.

Authors:  Jutatip Panaampon; Ryusho Kariya; Seiji Okada
Journal:  Cancer Immunol Immunother       Date:  2022-03-09       Impact factor: 6.630

5.  Replicative potential of human natural killer cells.

Authors:  Hiroyuki Fujisaki; Harumi Kakuda; Chihaya Imai; Charles G Mullighan; Dario Campana
Journal:  Br J Haematol       Date:  2009-03-26       Impact factor: 6.998

Review 6.  Expansion and activation of natural killer cells for cancer immunotherapy.

Authors:  Duck Cho; Dario Campana
Journal:  Korean J Lab Med       Date:  2009-04

Review 7.  "Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy.

Authors:  Senthamil R Selvan; John P Dowling
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

8.  Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line.

Authors:  Duk Seong Bae; Jae Kwon Lee
Journal:  Blood Res       Date:  2014-09-25

Review 9.  Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.

Authors:  Markus Granzin; Juliane Wagner; Ulrike Köhl; Adelheid Cerwenka; Volker Huppert; Evelyn Ullrich
Journal:  Front Immunol       Date:  2017-04-26       Impact factor: 7.561

10.  Autologous immune enhancement therapy: A case report of a stage IV colonic cancer.

Authors:  Baskar Subramani; Kananathan Ratnavelu; Chithra Ramanathan Pullai; Kohila Krishnan; Sheela Devi Sugadan; Xuewen Deng; Terunuma Hiroshi
Journal:  Oncol Lett       Date:  2013-03-12       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.